Investigational drugs for the treatment of olfactory dysfunction
ReviewHumans
- Design
- Review
- Subjects
- Not applicable; a narrative review
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- What treatments exist for olfactory dysfunction, grouped by topical versus systemic administration, using post-COVID smell loss as the model
What the authors reported
Comparing topical and systemic treatment results can suggest whether an olfactory disorder has a peripheral or central origin, the authors argue, and treatments tested in COVID-19 smell loss might also be options for neurodegenerative olfactory disease. The abstract does not name palmitoylethanolamide.
Limits of this study
A narrative review and expert opinion, not new data. PEA is not mentioned in the abstract. Funding and conflicts not stated in the abstract.
Source
PubMed 35983993 · doi:10.1080/13543784.2022.2113054
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.